Summary:
- The article discusses a new Alzheimer's drug called lecanemab, which has shown promising results in a late-stage clinical trial.
- The study found that lecanemab was able to slow the cognitive decline in patients with early-stage Alzheimer's disease by 27% compared to a placebo.
- Importantly, the drug was also found to triple the risk of death, raising concerns about its safety and potential side effects, which will need to be further investigated.